Search
Romidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexSecnidazole
go.drugbank.com/drugs/DB12834ApprovedInvestigationalSecnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. … Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent.
Products: SECNICHEN POLVO PARA RECONSTITUIR A SUSPENSIÓN ORAL, SECNIDAZOL PPS (POLVO PARA RECONSTITUIR A SUSPENSIÓN)Relacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalOriginally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pivoted toward oncology as a potent sensitizing … Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist.
alpha-Tocopherol acetate
go.drugbank.com/drugs/DB14003ApprovedMoreover, RRR-alpha-tocopherol acetate is a relatively stabilized form of vitamin E that is most commonly used as a food additive when needed [A32451]. … At the moment however, there exists a lack of formal data and evidence to support any such additional indications for vitamin E use.
Mixtures: One A Day Tab, One A Day Advance FemCategories: Compounds used in a research, industrial, or household settingIfosfamide
go.drugbank.com/drugs/DB01181ApprovedInvestigationalIfosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Categories: Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexProducts: IFOSFAMIDA 1G POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE.Inotuzumab ozogamicin
go.drugbank.com/drugs/DB05889ApprovedInvestigationalInotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin … [L938] A month later, inotuzumab ozogamicin was also approved by the FDA.[L50542]
Categories: P-glycoprotein substrates with a Narrow Therapeutic IndexDeutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigationalDeutivacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. … It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.
Icodextrin
go.drugbank.com/drugs/DB00702ApprovedInvestigationalIt is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport via peritoneal lymphatic pathways. … Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers.
Mixtures: EXTRANEAL CON ICODEXTRIN AL 7.5%Categories: Compounds used in a research, industrial, or household settingArtenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalArtenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label]. … It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.
Elivaldogene autotemcel
go.drugbank.com/drugs/DB16746ApprovedGene therapy with autologous hematopoietic stem cells was introduced and investigated as a possible treatment for patients with adrenoleukodystrophy. … Elivaldogene autotemcel is a gene therapy consisting of genetically modified autologous cells.